News Denmark's Genmab prepares for $500m US IPO Antibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, is preparing for a $500 million US IPO.
News ‘Trojan horse’ cancer drug shows promise in multiple tumour ... A new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
News J&J rumoured to be sizing up $12bn Genmab acquisition Speculation mounts that J&J will bid for R&D partner
News Novartis' Arzerra gains CLL approval Development partner Genmab says drug approved in relapsed disease.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
